MedPath
HSA Approval

MICROGYNON 30 TABLET

SIN04834P

MICROGYNON 30 TABLET

MICROGYNON 30 TABLET

June 26, 1990

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER (SOUTH EAST ASIA) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAYER (SOUTH EAST ASIA) PTE LTD
Licence HolderBAYER (SOUTH EAST ASIA) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, SUGAR COATED

ORAL

Medical Information

G03AA07

levonorgestrel and ethinylestradiol

Manufacturer Information

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER WEIMAR GMBH UND CO. KG

Active Ingredients

ETHINYLESTRADIOL

0.03 mg

Ethinylestradiol

LEVONORGESTREL

0.15 mg

Levonorgestrel

Documents

Package Inserts

MICROGYNON 30 TABLET PI.pdf

Approved: March 22, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MICROGYNON 30 TABLET - HSA Approval | MedPath